Johnson & Johnson (JNJ)
After hours:
| Previous close | 164.92 |
| Open | 163.00 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's range | 162.82 - 166.22 |
| 52-week range | 155.72 - 186.69 |
| Volume | |
| Avg. volume | 6,961,375 |
| Market cap | 432.801B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 24.60 |
| EPS (TTM) | 6.73 |
| Earnings date | 18 Apr 2023 |
| Forward dividend & yield | 4.52 (2.74%) |
| Ex-dividend date | 17 Feb 2023 |
| 1y target est | 183.63 |
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Business Wire
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
NEW BRUNSWICK, N.J., February 02, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).
- Motley Fool
Looking for a Reliable Dividend Payer? Consider Buying This Blue-Chip Stock
While there is no perfect dividend stock, Johnson & Johnson (NYSE: JNJ) is about as great as they come. Since its founding more than 130 years ago, J&J established itself as the leading pharmaceutical company in the world. Just how big is J&J?
